Managed

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Merck diversifies its Big Data agenda

Merck diversifies its Big Data agenda

By

Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.

Young adult ACA enrollment holds steady

Around 25% of 18-34 year-olds have signed up for coverage. Obama's FunnyorDie appearance drives HHS traffic.

Managed Markets: Operation Patient-Centricity

Managed Markets: Operation Patient-Centricity

As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?

Retail pharmacies up consumer satisfaction

Retail pharmacies up consumer satisfaction

By

A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.

CMS projects healthcare spending to rise

CMS projects healthcare spending to rise

By

Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards

Researchers propose new Rx adherence model

Researchers propose new Rx adherence model

By

Researchers say using additional data points offers greater insight into patient-adherence patterns.

Employer, employee healthcare costs to rise in 2014

By

Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.

CVS joins prescription crackdown

By

The drugstore chain says it has cut off over-prescribers of tightly controlled medications.

Eylea outduels Lucentis for physician mindshare, survey shows

Eylea outduels Lucentis for physician mindshare, survey shows

By

Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.

Managed Markets: Pursuing the Payer

Managed Markets: Pursuing the Payer

While payers' proclivity for print is well-known, many prefer to receive pharma resources digitally, research shows. Joe Dysart on tools that work for this segment.

Email Newsletters